Polio eradication

SINOVAC Polio Vaccine Prequalified by WHO

Retrieved on: 
Thursday, June 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, GPEI, World Health Organization, UN, Polio, OPV, Global Polio Eradication Initiative, Research, Food, Immunization, Infection, Influenza A virus subtype H1N1, United Nations, Poliovirus, VAPP, Polio eradication, Sinovac Biotech, Mouth, Environment, Hepatitis A, Pain, WHO, Fever, Chickenpox, Motor neuron, Vaccine, Feces, Campus Biotech, Saliva, COVID-19, NASDAQ, Prevalence, CoronaVac, Water, Public health, Mumps, Profile, EV71, World

The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.

Key Points: 
  • The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.
  • The vaccine can be used sequentially with oral polio attenuated live vaccine (OPV).
  • With the impact of the global COVID-19 pandemic, countries where wild polio strains still exist have experienced an increasing prevalence of polio cases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combined and new technology vaccine products in the pipeline.

Intravacc's inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Retrieved on: 
Tuesday, July 20, 2021
Polio, Medical specialties, Medicine, Vaccination, Vaccines, Polio vaccine, Polio eradication, Vaccine, Global Polio Eradication Initiative, Pulse Polio, Contact immunity

This multivalent polio vaccine was developed by Intravacc for the purpose of providing low and middle-income countries with the opportunity to produce their own safe polio vaccine in the context of the global polio eradication initiative.

Key Points: 
  • This multivalent polio vaccine was developed by Intravacc for the purpose of providing low and middle-income countries with the opportunity to produce their own safe polio vaccine in the context of the global polio eradication initiative.
  • It will also help to close the gap between demand and supply of safe and effective Inactivated Polio Vaccines (IPV) for millions of infants in need of immunization against poliovirus.
  • As a result of the current SarsCov-2 pandemic, the vaccination campaigns to eradicate polio were either put on hold or delayed worldwide.
  • The pandemic may also further delay polio eradication due to indirect effects on vaccine supplies and financial resources.

Intravacc's inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Retrieved on: 
Tuesday, July 20, 2021
Polio, Medical specialties, Medicine, Vaccination, Vaccines, Polio vaccine, Polio eradication, Vaccine, Global Polio Eradication Initiative, Pulse Polio, Contact immunity

This multivalent polio vaccine was developed by Intravacc for the purpose of providing low and middle-income countries with the opportunity to produce their own safe polio vaccine in the context of the global polio eradication initiative.

Key Points: 
  • This multivalent polio vaccine was developed by Intravacc for the purpose of providing low and middle-income countries with the opportunity to produce their own safe polio vaccine in the context of the global polio eradication initiative.
  • It will also help to close the gap between demand and supply of safe and effective Inactivated Polio Vaccines (IPV) for millions of infants in need of immunization against poliovirus.
  • As a result of the current SarsCov-2 pandemic, the vaccination campaigns to eradicate polio were either put on hold or delayed worldwide.
  • The pandemic may also further delay polio eradication due to indirect effects on vaccine supplies and financial resources.

SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, Medical specialties, Vaccination, Medicine, Polio, Vaccines, Medical research, Polio vaccine, Vaccine, Sinovac Biotech, Contact immunity, Polio eradication, Poliomyelitis, SINOVAC, POLIOMYELITIS, SINOVAC

Inactivated polio vaccine (IPV) contains no live virus and, thus, carries no risk of emergence from vaccine-derived poliovirus (VDPV) or vaccine-associated paralytic polio (VAPP).

Key Points: 
  • Inactivated polio vaccine (IPV) contains no live virus and, thus, carries no risk of emergence from vaccine-derived poliovirus (VDPV) or vaccine-associated paralytic polio (VAPP).
  • As the COVID-19 pandemic impact persists, countries where the wild polio strain still exist have been experiencing an increase in prevalence of polio casese.
  • In 2014, SINOVAC entered into a license agreement with Intravacc to develop and commercialize the Sabin strain based Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.
  • According to the agreement, SINOVAC committed to commercializing the vaccine in China, inclusive of conducting clinical trials, obtaining regulatory approval, commercializing the sIPV vaccine and seeking pre-qualification by WHO.

Global NGO expands use of PharmaJet for Polio Eradication Campaigns

Retrieved on: 
Tuesday, March 9, 2021
Infectious diseases, Pharmaceutical, Health, Medical devices, Polio, Medical specialties, Vaccination, Medicine, Clinical medicine, Polio eradication, Vaccine, Polio in Pakistan, Pulse Polio

PharmaJet , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis Needle-free Injection System in polio eradication campaigns.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis Needle-free Injection System in polio eradication campaigns.
  • This brings the total number of children with planned or completed polio vaccinations using PharmaJet Needle-Free Injection devices to close to 3 million.
  • While there is no cure for polio, the disease can be prevented through the administration of a simple and effective vaccine.
  • That is why efforts are underway across the globe to rapidly boost immunity levels in children and protect them from polio paralysis.

Intravacc's Sabin Inactivated Polio vaccine (sIPV), out-licensed to LG Chem, receives WHO prequalification

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Medicine, Vaccination, Vaccines, Virology, Polio vaccine, Polio eradication, Vaccine, Polio, Pentavalent vaccine, Attenuated vaccine

The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.

Key Points: 
  • The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.
  • The company will supply the vaccine to 70 countries in the Middle East, Africa and Southeast Asia starting in January 2021.
  • Intravacc will receive milestones and low single digit royalties for its considerable role in the development of this vaccine.
  • To reduce the use of the virulent vaccine derived polioviruses, a switch to inactivated polio vaccines (IPV) was desired.

Intravacc's Sabin Inactivated Polio vaccine (sIPV), out-licensed to LG Chem, receives WHO prequalification

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Medicine, Vaccination, Vaccines, Virology, Polio vaccine, Polio eradication, Vaccine, Polio, Pentavalent vaccine, Attenuated vaccine

The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.

Key Points: 
  • The vaccine was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative.
  • The company will supply the vaccine to 70 countries in the Middle East, Africa and Southeast Asia starting in January 2021.
  • Intravacc will receive milestones and low single digit royalties for its considerable role in the development of this vaccine.
  • To reduce the use of the virulent vaccine derived polioviruses, a switch to inactivated polio vaccines (IPV) was desired.

Breakthrough in the Global Battle Against Polio: AJ Vaccines Granted WHO Prequalification for New Polio Vaccine

Retrieved on: 
Wednesday, April 22, 2020
Research, Medical devices, Infectious diseases, Hospitals, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Medical specialties, Vaccination, Medicine, Polio, RTT, Vaccines, Virology, Polio eradication, Polio vaccine, Vaccine, Universal Immunization Programme, Contact immunity

Looking ahead, AJ Vaccines dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.

Key Points: 
  • Looking ahead, AJ Vaccines dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
  • View the full release here: https://www.businesswire.com/news/home/20200421005973/en/
    Jesper Helmuth Larsen, CEO of AJ Vaccines (Photo: Business Wire)
    The development of the first stand-alone dose sparing polio vaccine is a milestone for the significant investment and innovation in the Danish based vaccine production.
  • The dose sparing IPV is shown to provide protection comparable to that provided by other inactivated polio vaccines currently available.
  • The dose sparing technology secures a much-needed increase in supply, helping to meet the increasing demand for inactivated polio vaccines to support the Global Polio Eradication Initiative, concludes Jrme Cabannes, COO AJ Vaccines.

Alwaleed Philanthropies Joins the Bill & Melinda Gates Foundation and Partners With New Commitment to Eradicate Polio

Retrieved on: 
Thursday, November 21, 2019
Articles, Health, Medical specialties, Global Polio Eradication Initiative, Polio eradication, Polio, Bill Gates, Bill & Melinda Gates Foundation, India National PolioPlus

The Global Polio Eradication Initiative (GPEI) 'Endgame Strategy 2019-2023' aims to tackle the final obstacles to the eradication of polio and sustain a polio-free future.

Key Points: 
  • The Global Polio Eradication Initiative (GPEI) 'Endgame Strategy 2019-2023' aims to tackle the final obstacles to the eradication of polio and sustain a polio-free future.
  • Bill Gates, representing the Bill & Melinda Gates Foundation, which is one of the leading partners of the GPEI, announced and recognised the first funders of the strategy and called for more donors to come forward in a key pledge moment for the organisation.
  • Alwaleed Philanthropies' donation of US $2 million to GPEI will support the creation of action plans to expand access to polio vaccination and help reach children everywhere.
  • That's why I am here today with these renowned partners, calling on others to join us in this last battle to end polio for good."

Alwaleed Philanthropies Joins the Bill & Melinda Gates Foundation and Partners With New Commitment to Eradicate Polio

Retrieved on: 
Thursday, November 21, 2019
Articles, Health, Global health, Medical specialties, Health campaigns, RTT, Global Polio Eradication Initiative, Polio eradication, Eradication of infectious diseases, Polio, World Health Organization, Bill Gates

The Global Polio Eradication Initiative (GPEI) 'Endgame Strategy 2019-2023' aims to tackle the final obstacles to the eradication of polio and sustain a polio-free future.

Key Points: 
  • The Global Polio Eradication Initiative (GPEI) 'Endgame Strategy 2019-2023' aims to tackle the final obstacles to the eradication of polio and sustain a polio-free future.
  • Bill Gates, representing the Bill & Melinda Gates Foundation, which is one of the leading partners of the GPEI, announced and recognised the first funders of the strategy and called for more donors to come forward in a key pledge moment for the organisation.
  • Alwaleed Philanthropies' donation of US $2 million to GPEI will support the creation of action plans to expand access to polio vaccination and help reach children everywhere.
  • Afterwards, HRH Prince Alwaleed Bin Talal met with Bill Gates, with whom he has a long and productive relationship, to discuss the remaining challenges in global infectious disease eradication.